

Immune-proteome landscape post-COVID19

1 **Title:** Immuno-proteomic profiling reveals abundant airway CD8 T cells and ongoing
2 epithelial injury in prolonged post-COVID19 respiratory disease

3

4 Authors: Bavithra Vijayakumar^{1,2,3,+}, Karim Boustani^{1,4,+}, Patricia P. Ogger^{1,+}, Artemis
5 Papadaki^{5,+}, James Tonkin^{1,3}, Christopher M. Orton^{1,3}, Poonam Ghai¹, Kornelija
6 Suveizdyte¹, Richard J. Hewitt^{1,3}, Robert J. Snelgrove^{1,4}, Philip L. Molyneaux^{1,3},
7 Justin L. Garner^{2,3}, James E. Peters^{5,*}, Pallav L. Shah^{1,2,3,*}, Clare M. Lloyd^{1,4*} and
8 James A. Harker^{1,4,*}

9

10 ¹National Heart and Lung Institute, Imperial College London, London, UK

11 ²Chelsea and Westminster Hospital, London, UK

12 ³Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation
13 Trust, London, UK

14 ⁴Asthma UK Centre for Allergic Mechanisms of Asthma

15 ⁵Centre for Inflammatory Disease, Dept of Immunology and Inflammation, Imperial
16 College London, Hammersmith Hospital, London, UK

17 +denotes equal contribution

18 *co-senior authors

19

20 Lead contact: Dr James A Harker, j.harker@imperial.ac.uk

21 Sir Alexander Fleming Building, National Heart and Lung Institute, South Kensington
22 Campus, Imperial College London, London, UK. SW7 2AZ.

Immune-proteome landscape post-COVID19

23 **Highlights**

24

25 • The post-COVID19 airway is characterized by increased cytotoxic lymphocytes.

26

27 • Distinct airway proteomes are associated with the airway immune cell landscape.

28

29 • The peripheral blood does not predict immune-proteome alterations in the airway
30 post-COVID19.

31

32 • Persistent abnormalities in the airway immune-proteome post-COVID19 airways
33 correlate with ongoing epithelial damage.

34

Immune-proteome landscape post-COVID19

35 **Summary**

36 Some patients hospitalized with acute COVID19 suffer respiratory symptoms that
37 persist for many months. To characterize the local and systemic immune responses
38 associated with this form of 'Long COVID', we delineated the immune and proteomic
39 landscape in the airway and peripheral blood of normal volunteers and patients from
40 3 to 6 months after hospital discharge. The bronchoalveolar lavage (but not
41 peripheral blood) proteome was abnormal in patients with post-COVID19 lung
42 disease with significantly elevated concentration of proteins associated with
43 apoptosis, tissue repair and epithelial injury. This correlated with an increase in
44 cytotoxic lymphocytes (especially tissue resident CD8⁺ T cells), lactate
45 dehydrogenase and albumin (biomarkers of cell death and barrier integrity). Follow-
46 up of a subset of these patients greater than 1-year post-COVID19 indicated these
47 abnormalities resolved over time. Collectively, these data indicate that COVID-19
48 results in a prolonged change to the airway immune landscape in those with
49 persistent lung disease, with evidence of cell death and tissue repair linked to
50 ongoing activation of cytotoxic T cells.

51

52

53 **Key words:** respiratory viral infection, tissue resident memory, COVID19, SARS-
54 CoV-2, airways

Immune-proteome landscape post-COVID19

55 **Introduction**

56

57 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) related coronavirus
58 disease (COVID19) manifests as a spectrum of acute illnesses ranging from mild
59 respiratory symptoms to severe, sometimes fatal, respiratory failure (Docherty et al.,
60 2020). While the acute impact of COVID19 on morbidity and mortality is well-
61 documented, we are still in the infancy of understanding the longer-term
62 consequences. Morbidity from a range of persistent symptoms, including
63 breathlessness, fatigue and memory impairment have been noted in patients
64 recovering after the acute illness and described under the umbrella term of “long
65 COVID” (Nalbandian et al., 2021; Sigfrid et al., 2021). Complex respiratory
66 complications have been found in up to 18.4% of inpatients (Drake et al., 2021), and
67 persistent breathlessness reported in more than 50% of patients recovering from
68 COVID19 (Mandal et al., 2021). The underlying aetiology for persistent respiratory
69 morbidity is likely to be multifactorial but may be due to persistent parenchymal
70 abnormalities and resultant ineffective gaseous exchange. Persistent radiological
71 abnormalities post-COVID19 are common and may be present even up to 6 months
72 post hospital discharge (Fabbri et al., 2021; Guler et al., 2021; Han et al., 2021; Myall
73 et al., 2021). There is, therefore, a pressing need to understand the molecular and
74 cellular basis of post-COVID19 pulmonary syndromes.

75

76 The acute immunological and inflammatory events that occur during human
77 respiratory virus infections, including SARS-CoV-2, are relatively well described
78 (Harker and Lloyd, 2021). In contrast, the immunological landscape of the human
79 respiratory tract after recovery from acute viral infection is poorly understood. SARS-
80 CoV-2 infection results in formation of long-lasting systemic immunological memory,
81 with virus-specific antibodies and T cell responses still detectable in the majority of
82 those infected at least 8 months post infection and higher titers seen in previously
83 hospitalized individuals (Dan et al., 2021). Circulating lymphocyte counts and the
84 function and frequency of monocytes are also reduced during acute disease, but they
85 appear to return to normal shortly after resolution of acute disease (Mann et al.,
86 2020; Scott et al., 2020). Likewise, plasma concentrations of inflammatory mediators
87 such as IL-6 and CXCL10, that are highly elevated in acute disease, reduce as
88 individuals recover (Rodriguez et al., 2020). Together, this suggests that systemic
89 inflammatory and immune responses associated with acute disease severity resolve
90 in line with recovery from the acute symptoms. It therefore remains unclear if the
91 severity of inflammation during acute disease is associated with the persistent

Immune-proteome landscape post-COVID19

92 respiratory pathology seen in some SARS-CoV-2 infected individuals months after
93 infection, or if there is ongoing inflammation in these individuals.

94

95 This study sought to examine the relationship between the immune system and
96 respiratory pathology post-COVID19. The immune cell and proteomic composition of
97 the airways and peripheral blood were analyzed in a group of previously hospitalized
98 COVID19 patients with persistent radiological abnormalities in their lungs over 3
99 months post discharge. In comparison to healthy individuals, the post-COVID19
100 airway showed substantial increases in activated tissue resident memory CD8⁺ and
101 CD4⁺ TRM, and an altered monocyte pool. The airway proteome was also distinct
102 from that observed in healthy individuals, with elevation in proteins associated with
103 ongoing cell death, loss of barrier integrity and immune cell recruitment. Importantly,
104 none of these alterations were predicted by changes in the proteome or immune cells
105 of the matched peripheral blood. Moreover, the scale of these alterations was not
106 linked to the initial severity of disease while in hospital but instead was heterogenous.
107 Some individuals displaying heightened T cell responses associated with significant
108 increases in CXCR3 chemokines in the airways and linked to prolonged epithelial
109 damage and extracellular matrix (ECM) dysregulation, while other individuals
110 exhibited a return to relative airway homeostasis. Subsequent long-term follow-up
111 also suggested that these ongoing changes to the airway landscape progressively
112 return to normal.

Immune-proteome landscape post-COVID19

113 **Results**

114

115 *Increased airway lymphocyte numbers characterize patients recovering from*
116 *hospitalization with SARS-CoV-2*

117

118 We recruited 38 patients undergoing bronchoscopy for investigation of persistent
119 respiratory abnormalities 3-6 months following infection after acute SARS-CoV-2
120 infection (post-COVID19) (**Figure 1A**). All patients had both ongoing respiratory
121 symptoms and radiological pulmonary abnormalities on computed tomography (CT)
122 scanning. We obtained plasma samples from peripheral blood and bronchoalveolar
123 lavage (BAL) fluid from their airways. We stratified the post-COVID19 cohort based
124 on the level of respiratory support used during their initial hospitalization with acute
125 COVID19, into moderate (no or minimal oxygen administered), severe (non-invasive
126 ventilation) and very severe (invasive ventilation). To provide a control group, we
127 used BAL and plasma samples obtained from 10 healthy volunteers recruited prior to
128 the COVID19 pandemic (demographic information in **Table S1**).

129

130 We first compared the cellular composition of BAL fluid in post-COVID19 patients to
131 healthy controls (HC) by flow cytometry. Post-COVID19 patients had a significantly
132 higher numbers of cells in their airways compared to the healthy volunteers (**Figure**
133 **1B**). This increased cellularity was due to significantly elevated numbers of airway T
134 and B cells, and a trend towards increased airway macrophages (AM), CD56⁺CD3⁻
135 (natural killer, NK) cell and CD56⁺CD3⁺ (NKT) cell numbers, while CD14⁺ monocyte,
136 eosinophil and neutrophil numbers were similar to those found in healthy controls
137 (**Figure 1C**). As a proportion of airway leukocytes, CD14⁺ monocytes and neutrophils
138 were decreased in patients recovering from COVID19 compared to healthy controls
139 (**Figure S1A**). There was no association between the severity of acute COVID19 in
140 hospital and the immune cell composition of the post-COVID19 airways (**Figure 1C**).
141 In contrast to the peripheral lymphopenia that is associated with acute COVID19
142 (Chen and Wherry, 2020), we found that in this post-COVID19 patient cohort the
143 frequency of T cells, B cells and CD14⁺ monocytes in the peripheral blood was
144 broadly similar to healthy controls (**Figure S1B**), although the proportion of NK and
145 NKT cells was significantly decreased (**Figure S1B**). Collectively, these data indicate
146 that after recovery from severe SARS-CoV-2 infection, immune cell frequencies in
147 the peripheral blood are comparable to those in a group of age-matched controls. In
148 contrast, the immune landscape of the airways remains altered, being marked by
149 residual lymphocytes.

Immune-proteome landscape post-COVID19

150

151 *The post-COVID19 airway immune landscape displays a limited relationship to*
152 *inflammatory biomarkers found during acute disease*

153

154 Severe COVID19 has a distinctive clinical biomarker blood profile, characterized by
155 elevated inflammatory markers (including C-reactive protein (CRP) and ferritin),
156 elevated coagulation markers (D-dimer and fibrinogen), and lymphopenia (Guan et
157 al., 2020). At the time of hospitalization, our patients displayed a similar pattern of
158 clinical laboratory test abnormalities (**Table S1**). We therefore examined whether
159 there was any association between the peak levels (or nadir in the case of
160 lymphocyte count) of these clinical biomarkers measured during acute hospitalization
161 and the immune cell composition of the airways at 3 months following discharge. Of
162 the 5 biomarkers measured, ferritin correlated (Spearman rho > 0.4) with total airway
163 monocytes, specifically classical and intermediate monocytes, and eosinophils, and
164 inversely correlated with AM (**Table S2**). Total airway B cells correlated with peak D-
165 dimer, while airway eosinophils correlated with lowest lymphocytes. None of the
166 biomarkers correlated with follow up airway T cell, NK cell or neutrophil numbers, and
167 fibrinogen and WCC showed no substantial correlation with any airway immune cell
168 analyzed. Taken together these data suggest that the post-COVID19 airway immune
169 cell composition shows a limited relationship with the severity of initial acute disease.
170 This observation is supported by the lack of differences in immune cell composition
171 when segregating between moderate, severe and very severe patients (**Figure 1**).

172

173 *The post-COVID19 airway displays a proteome profile distinct from that found in the*
174 *circulation.*

175

176 Since clinical biomarkers did not reveal a relationship between acute disease and
177 prolonged pathology and immune responses in the lungs post discharge, we next
178 evaluated the airway and blood (plasma) proteomes at follow-up. We used the Olink
179 proteomics platform to measure 435 unique proteins (**Supplementary File 1A**) in 19
180 post-COVID19 patients and 9 healthy volunteers. The proteins measured were highly
181 enriched for those involved in immuno-inflammatory processes (**Supplementary File**
182 **1B-C**).

183

184 Principal components analysis (PCA) of BAL fluid proteomes revealed differences
185 between post-COVID19 patient and healthy control samples (**Figure 2A**), with
186 separation of case and controls most evident along PC1. In plasma, PCA also

Immune-proteome landscape post-COVID19

187 revealed differences in post-COVID19 patients and healthy controls, most evident
188 along PC2, although the differences appeared less marked than for BAL. However, in
189 both BAL and plasma there was considerable overlap in the spatial location of post-
190 COVID19 and healthy control samples in the PCA plots. Unsupervised hierarchical
191 clustering revealed two major clusters of samples in BAL, one consisting
192 predominantly of post-COVID19 samples and the other predominantly healthy
193 controls (**Figure S2A**), although, as with the PCA, some patient and control samples
194 were grouped together. In contrast, in plasma, there was no visible structure to the
195 clustering and lack of clear separation of cases and control samples (**Figure S2B**).
196 These analyses indicate that post-COVID19 syndromes are reflected to a much
197 greater extent in the airway proteome than the peripheral blood. They also suggest
198 that there is considerable heterogeneity in the BAL and blood proteomes of post-
199 COVID19 patients, with some patients displaying similar profiles to that of healthy
200 controls, despite persistent symptoms and radiological findings.

201 We next performed differential protein abundance analysis comparing post-COVID19
202 cases with healthy controls. In BAL fluid, we identified 22 proteins with significantly
203 altered concentration (5% false discovery rate, FDR) (**Figure 2B-C, Supplemental**
204 **File 1D**). These were all upregulated in post-COVID19 patients compared to healthy
205 controls (**Figure 2C**). In order to provide a succinct and standardised nomenclature,
206 we report proteins by the symbols of the genes encoding them (see **Supplementary**
207 **File 1A** for a mapping of symbols to full protein names). The proteins that were most
208 significantly differentially abundant between post-COVID19 patients and healthy
209 controls were: SERPINA7 (thyroxine binding globulin), DPP4 (dipeptidyl peptidase 4),
210 SERPINA5 (plasma serine protease inhibitor), KLK6 (kallikrein related peptidase-6),
211 LYVE1 (Lymphatic vessel endothelial hyaluronic acid receptor 1), AREG
212 (amphiregulin), F3 (factor 3), FLT3LG (Fms-related tyrosine kinase 3 ligand), QPCT
213 (glutaminyl-peptide cyclotransferase), and SRC (Proto-oncogene tyrosine-protein
214 kinase Src) (**Figure 2C-D**). Pathway annotation of the 22 upregulated proteins using
215 String-DB highlighted “leucocyte activation”, “regulation of cell death”, “response to
216 injury” and “response to wounding” (**Supplemental File 1E**). Next, we analyzed the
217 relationship between the 22 differentially abundant proteins and the airway immune
218 cell proportions. Neutrophils most strongly correlated with AREG and LDLR (low
219 density lipoprotein receptor), while monocyte proportions correlated with F3,
220 FLT3LG, MB (myoglobin) and IL1RN (IL-1 receptor antagonist protein) (**Figure 2E**).
221 T cells, despite being significantly elevated in the airways of post-COVID19 patients,
222 displayed only weak correlations with the differentially abundant proteins.

Immune-proteome landscape post-COVID19

223

224 In contrast to BAL, no significant differences between protein levels were detected in
225 plasma in post-COVID19 patients versus healthy controls (**Supplemental File 1F**).
226 Comparison of the estimated \log_2 fold changes for the 22 proteins upregulated in
227 post-COVID19 BAL fluid with the estimated \log_2 fold changes for these same
228 proteins in plasma revealed no correlation (**Figure S2C-D**), indicating an absence of
229 any relationship between airway and plasma proteome changes.

230

231 The modest sample size and multiple testing burden of 435 proteins likely limited the
232 statistical power to detect differentially abundant proteins. To examine whether there
233 was evidence of signal in the proteomic data that was hidden by the hard-
234 thresholding in the differential abundance analysis, we examined quantile-quantile
235 (QQ) plots of the distribution of expected p-values under the null hypothesis of no
236 proteomic differences between cases and controls versus the observed p-values. For
237 both BAL and plasma, the QQ plots revealed substantial deviation from the diagonal
238 (albeit more so in BAL), indicating the presence of systematic differences between
239 post-COVID19 and healthy controls for plasma proteins as well as BAL proteins
240 (**Figure S3A**). Corroborating this, the distribution of p-values for the proteins was not
241 uniformly distributed, with skewing towards zero (**Figure S3B**). This is consistent with
242 the observation that there was separation of post-COVID19 and control samples on
243 the PCA plots for both BAL and plasma. In summary, these data suggests that there
244 are differences in both the BAL and plasma proteomes of post-COVID19 cases
245 compared to healthy controls, but that the effects are much stronger in BAL and this
246 study was underpowered to detect them in plasma.

247 To increase power, and investigate potential protein-protein relationships, we utilized
248 a network analysis method, Weighted Coexpression Network Analysis (WGCNA)
249 (Langfelder and Horvath, 2008; Zhang and Horvath, 2005), that leverages the
250 correlation between proteins to enable dimensionality reduction and thus reduce
251 multiple testing burden. We used WGCNA to identify modules of correlated proteins,
252 and then tested for association between these protein modules (represented
253 quantitatively by an eigenprotein value) and case/control status. In BAL fluid, this
254 revealed two modules ('red' and 'blue') associated with case/control status using a
255 5% FDR significance cut-off (**Figure 3A, Supplementary File 1G-I**). Applying a more
256 conservative Bonferroni corrected p-value threshold, only the red module remained
257 significant ($P_{\text{Bonferroni}} 0.03$).

Immune-proteome landscape post-COVID19

258 The red module consisted of 37 proteins (**Figure 3B, Supplementary File 1H**).
259 Overall, the red module was characterized by proteins associated with chemotaxis,
260 inflammation, cell death and repair. Examination of the levels of proteins in the red
261 module across samples highlighted both upregulation of individual proteins in post-
262 COVID19 patients versus healthy controls, and the co-upregulation of groups of
263 related proteins such as the CXCR3 chemokines (CXCL9, CXCL10 and CXCL11),
264 and IL1A (interleukin-1A) and its antagonist IL1RN (**Figure 3B**). We used the
265 STRING database to visualize known or predicted relationships between proteins in
266 the module (**Figure 3C, Methods**). To highlight putative key proteins in the red and
267 blue modules in a data-driven way, we identified hub proteins, defined as those that
268 are highly interconnected in the proteomic network defined by WGCNA
269 (**Supplementary File 1J**). This analysis identified CASP3 (caspase-3), EPCAM
270 (epithelial cell adhesion molecule), F3 and MB as hub proteins in the red module.
271 Notably, F3 and MB, an oxygen binding protein release of which is linked to muscle
272 damage, were also identified as upregulated in the univariate differential abundance
273 analysis (**Figure 2B-C**). CASP3 is a protein involved in cell death, EPCAM and
274 KRT19 (Keratin-19) are indicative of epithelial cell debris within the BAL, and TGFA
275 (transforming growth factor A) is an EGFR ligand involved in EC repair. The
276 presence of CASP3, EPCAM, KRT19 and TGFA in the red eigenprotein module
277 therefore suggests that one of the key features of the post-COVID19 airway is the
278 presence of ongoing epithelial injury and repair.

279 As with the red module, blue module proteins were predominantly upregulated in
280 post-COVID19 versus healthy control BAL (**Figure S4A**). The blue module was
281 larger than the red module, containing 108 proteins involved in a wide range of
282 biological activities. Several members were involved in cell adhesion and immune
283 cell signaling. The hub proteins in the blue module were CD93 (Complement
284 component C1q receptor), COMP (Cartilage oligomeric matrix protein), IGFBP3
285 (Insulin-like growth factor-binding protein 3), IL1R2 (Interleukin-1 receptor type 2),
286 LYVE1, MMP2 (72 kDa type IV collagenase), NCAM1 (Neural cell adhesion molecule
287 1), SELL (L-selectin), TIE1 (Tyrosine-protein kinase receptor Tie-1), TNXB
288 (Tenascin-X) and VASN (Vasorin) (**Figure S4B**). Of these, LYVE1 and VASN were
289 also identified in the differential abundance analysis.

290 In contrast to the BAL network analysis, no protein modules in plasma were
291 associated with case-control status. These results suggest that persistent post-
292 COVID19 respiratory abnormalities have a demonstrable proteomic signature in BAL

Immune-proteome landscape post-COVID19

293 that is distinct compared to that of healthy control BAL. In contrast, we were unable
294 to detect changes in the plasma proteome of post-COVID19 patients, even with the
295 enhanced statistical power provided by the WGCNA method.

296
297 *CXCR3 ligands and signs of ongoing epithelial damage correlate with airway T cell*
298 *and monocyte responses*

299

300 Given that the airways of post-COVID19 patients displayed a distinct proteome
301 alongside elevated numbers of T cells, B cells and NK cells, we next sought to
302 determine which specific proteins might be linked to distinct immune cell populations.
303 Testing for associations between BAL fluid proteins and immune cell composition in
304 post-COVID19 patients revealed several significant findings (**Figure 4A and**
305 **Supplemental file 1K**). The proportion of monocytes in the airways was significantly
306 associated with a range of airway proteins, including the CCR7 ligand CCL19, the
307 CXCR3 ligands CXCL9 and 11, TRAIL (TNFSF10), and BAFF (TNFSF13B) (**Figure**
308 **4A**). CXCL9 and 11 also positively correlated with lymphocyte and T cell frequencies
309 and negatively correlated with airway macrophage frequencies in the BAL (**Figure**
310 **4A**). T cell frequencies were also positively correlated with SH2D1A (otherwise
311 known as SLAM associated protein or SAP).

312

313 Analysis of combined data from healthy controls and post-COVID19 patients
314 revealed a composite score reflecting CXCL9, CXCL10 and CXCL11 levels, CXCL9,
315 CXCL10 and CXCL11, although no significant correlation was seen with CD3⁺CD56⁺
316 NKT cells (**Figure 4B**). Within the post-COVID19 data set (as CD16 was not present
317 in historic flow data used for healthy controls), total monocyte frequencies also
318 correlated with average CXCR3 ligand expression (**Figure 4C**). Analysis of
319 subpopulations revealed the proportion that were intermediate (CD14⁺CD16⁺)
320 monocytes positively correlated with CXCR3 ligands, while CD14⁺ monocytes
321 displayed a negative correlation, and CD16⁺ monocytes displayed no correlation
322 (**Figure 4C**). T cell proportions in the airways correlated tightly with the concentration
323 of CD8a protein, but not CD4, in the BAL (**Figure 4D**), suggesting the increased
324 airway T cells are most likely the result of increased CD8⁺ T cell frequencies.

325

326 Given the robust correlation of the CXCR3 ligands, particularly with T cells, we next
327 sought to determine the relationship between T cell frequencies and other members
328 of the red module, specifically those indicative of ongoing epithelial damage in the
329 post-COVID19 airways. CD8a correlated strongly with the concentrations of CASP3

Immune-proteome landscape post-COVID19

330 and EPCAM, concomitant with two of the differentially expressed proteins: MB and
331 DPP4 (**Figure 4E**). Collectively, these data suggest that proteins linked to the
332 recruitment of T cells, especially cytotoxic T cells, are strongly associated with
333 proteins that are both indicative of ongoing epithelial damage and upregulated in the
334 airways post-COVID19.

335

336 To further evaluate this and confirm the presence of increased damage in the post-
337 COVID19 airway, we measured DPP4, alongside 2 markers of damage not analyzed
338 through Olink, albumin and lactate dehydrogenase (LDH) in an expanded cohort of
339 healthy controls and post-COVID19 patients (**Figure 4F**). All 3 molecules were
340 significantly upregulated in the airways of patients post-COVID19 compared to
341 healthy controls, validating the observations made by Olink and confirming the
342 presence of ongoing damage within the respiratory tract in patients previously
343 hospitalized for COVID19.

344

345 *Distinct myeloid populations are present in the BAL compared to the peripheral blood*
346 *but do not correlate with ongoing airway damage post-COVID19*

347

348 Dysfunction of circulating classical monocytes is a hallmark of the initial, acute phase
349 of COVID19 infection (Mann et al., 2020). Given the correlations observed between
350 different airway monocyte populations and specific proteins in the BAL identified by
351 Olink, we further investigated the nature of airway and circulating myeloid cells in a
352 subgroup (n = 21) of post-COVID19 patients using high-parameter spectral
353 deconvolution cytometry. Unbiased FlowSOM analysis of the airway and circulating
354 myeloid cells revealed 10 distinct cell populations (**Figure 5A**), with marker analysis
355 suggesting these populations could be assigned to known subsets of monocytes or
356 dendritic cells (DCs). The circulation was dominated by CD14⁺ classical monocytes
357 (metacluster 1), which constituted most myeloid cells identified, while the airways
358 were more heterogenous, with the presence of intermediate monocytes, non-
359 classical monocytes and DCs (**Figure 5B**). Conventional gating of these myeloid
360 subsets (as shown in **Methods Figure 2**) confirmed these observations, with
361 classical monocytes being most abundant in the circulation, while CD16⁺ monocytes
362 were more frequent in the airways (**Figure 5C**). In comparison, DCs were identifiable
363 in both sites as pDCs, cDC1s and cDC2s, although were infrequent (**Figure 5D**).
364 Furthermore, airway monocyte activation status (as determined by CD86 and HLA-
365 DR expression) was not dependent on acute disease severity (**Figure 5E**). Likewise,
366 correlation of airway LDH and albumin concentrations revealed no strong

Immune-proteome landscape post-COVID19

367 associations between the relative abundance of different myeloid cells and ongoing
368 damage in the respiratory tract after COVID19 (**Figure 5F**); nor was there any
369 association between these cell types and DPP4 concentrations. Taken together this
370 indicates that while myeloid cell frequencies in the airways are associated with a
371 specific airway proteome landscape, this likely has limited association with ongoing
372 tissue damage after SARS-CoV-2 infection.

373

374 *The post-COVID19 airway is enriched for activated, tissue resident T cells*

375

376 The post-COVID19 airway showed significantly increased T cell numbers (**Figure**
377 **1C**), associated with a proteome linked to ongoing epithelial damage and repair
378 (**Figure 2**). FlowSOM analysis of the airway and circulating lymphocytes indicated
379 that 12 metaclusters with distinct protein expression profiles were present (**Figure**
380 **6A**). Several metaclusters were unique to either the blood or the airways, with
381 specifically clusters 1 and 10 only present in the airways, and cluster 5 only present
382 in the blood (**Figure 6B-C**). Marker expression analysis identified these metaclusters
383 (as described in **Figure 6B**), with the differential clusters being identified as tissue-
384 resident memory CD4 and CD8 T cells (metaclusters 1 and 10), and naïve CD4 T
385 cells (metacluster 5). Manual gating of T cell populations showed that while the blood
386 was enriched for naïve CD4 and CD8 T cells, the airways contained populations of
387 antigen-experienced CD4 and CD8 T cells (**Figure 6D**). Additionally, the airways
388 contained increased proportions of activated and tissue-resident memory (TRM) CD4
389 and CD8 T cells compared to blood (**Figure 6D**). Proportions of $\gamma\delta$ T cells and NK
390 cells in the airways and blood were comparable however there was a significant
391 increase in NKT cell proportions compared to blood (**Figure 6E**). Comparison of the
392 T cell dynamics in the post-COVID19 airways showed that airway CD4 T cells retain
393 a highly tissue resident phenotype (CD69⁺CD45RA⁻), with few naïve (CD45RA⁺) CD4
394 T cells observed, and the frequency of these 2 cell populations remains relatively
395 static, irrespective of the total number of CD4 T cells found in the airways (**Figure**
396 **6F**). In comparison, as CD8 T cell numbers increased in the airways, the proportion
397 displaying a CD45RA⁻CD69⁺ phenotype significantly increased, while those with a
398 CD45RA⁺ phenotype declined (**Figure 6F**).

399

400 In line with activated CD8 T cells, rather than activated CD4 T cells, being linked to
401 ongoing epithelial damage in the post-COVID19 airway there was a correlation ($r >$
402 0.4) between CD8, but not CD4, T cell proportions in the airways and the
403 concentrations of airway albumin and LDH (**Figure 6G**); this correlation was stronger

Immune-proteome landscape post-COVID19

404 when only CD69⁺ CD8 T cells were analyzed ($r = 0.5$, $p < 0.05$ for both Albumin and
405 LDH). LDH most significantly correlated with the proportion of CD69⁺ CD103⁻ CD8 T
406 cells in the airways ($r = 0.7$, $p < 0.001$), while albumin most significantly correlated
407 with the proportion of CD69⁺ CD103⁺ CD8 T cells in the airways ($r = 0.6$, $p < 0.001$),
408 highlighting distinct markers of damage were linked to different phenotypes of CD8 T
409 cells in the airway. Of note however, the CD8 T cell frequency did not correlate with
410 the concentration of DPP4 in the airways (**Figure 6G**). Deeper analysis revealed that
411 albumin concentrations were associated with reduced expression of molecules
412 associated with T cell activation on both CD103⁺ and CD103⁻ CD69⁺ CD8 T cells,
413 most notable CD28 and CD38 (**Figure 6H**). LDH concentrations meanwhile were
414 linked to downregulation of CD127 and, especially on CD103⁺ CD69⁺ CD8 T cells,
415 but upregulation of CD69 and CD27 (CD69: $r = 0.5$, $p < 0.05$; CD27: $r = 0.6$, $p < 0.05$,
416 **Figure 6H**). In contrast individuals with higher concentrations of DPP4 in the airways
417 appeared to possess CD8 TRM with higher expression of CRTH2 and CD38 (**Figure**
418 **6H**). No relationship was seen between the expression of activation markers on the
419 surface of CD8 TRM and the severity of disease in hospital (**Figure S5**). Taken
420 together, these results highlight the connection between T cells in the airways,
421 specifically CD8 TRM, and ongoing epithelial damage after recovery from COVID19,
422 and indicate differential CD8 T cell activation status may be associated with types of
423 damage within the airways.

424

425 *The enhanced airway immune cell frequencies seen post-COVID19 decline over time*

426

427 Acute COVID19 can result in persistent respiratory symptoms, and the data here
428 highlight the presence of substantial immunological and proteome alterations in the
429 airways of patients hospitalized with COVID19 up to 6 months after discharge. To
430 determine if these changes to the airways reduced over time, we examined 3
431 patients with continued lung CT abnormalities greater than 1 year following discharge
432 (**Table S3**). The total number of BAL cells recovered was greatly reduced in all 3
433 patients between the initial bronchoscopy and the 1 year follow up bronchoscopy,
434 down to comparable levels in healthy control airways (**Figure 7A**). Similarly, numbers
435 of T cells, B cells, NK cells and NKT cells were reduced to nearly or within the normal
436 range seen in the airways of healthy individuals (**Figure 7B**). In the 2 individuals with
437 elevated lymphocytes the ratio of CD4 to CD8 T cells increased (**Figure 7C**). In
438 accordance with this the proportion of CD8, but not CD4, T cells trended to decrease,
439 although the proportion of each that were of a TRM or activated (CD69⁺) phenotype,
440 remained similar between the 2 time points (**Figure 7D**). Fitting with progressive

Immune-proteome landscape post-COVID19

441 recovery trajectory airway DPP4 concentrations declined in the 2 patients with
442 elevated concentrations at the first bronchoscopy (**Figure 7E**), while CT abnormality
443 was also reduced in all 3 patients between the first CT and the follow up (**Figure 7F**).
444 Interestingly LDH was however increased between the first and second visit, while
445 albumin concentrations were unchanged, but also within the range of healthy controls
446 at both time points for all 3 patients analyzed (**Figure 7G**).

447

448 Collectively, our findings show ongoing changes to the immune and proteome
449 landscape of the airways, characterized by increased T cells and markers of
450 epithelial damage, several months after recovery from the acute phase of COVID19.
451 These changes, and lung pathology, do however appear to resolve over the longer (>
452 1 year) term.

453

Immune-proteome landscape post-COVID19

454 **Discussion**

455

456 Recovery from acute SARS-CoV-2 infection is associated with a wide range of
457 persistent symptoms including ongoing respiratory pathology. Here we examine the
458 airway and circulating landscape of patients previously hospitalized with COVID19,
459 finding they possess a distinct proteome and immunological profile in their airways,
460 but not peripheral blood, 3 to 6 months post recovery from acute infection. While
461 there is substantial heterogeneity between patients, common upregulated signals
462 include proteins associated with ongoing cell death, epithelial damage and tissue
463 repair; features that correlate with the presence of increased numbers of activated
464 tissue resident CD8 T cells within the airways. Importantly, preliminary evidence
465 suggests this altered airway landscape does improve over the long term, with
466 reductions in airway immune cell numbers 1 year post discharge from hospital.

467

468 The acute response to SARS-CoV-2 infection is characterized by upregulation of a
469 wide diversity of plasma proteins including members of the IFN pathway and their
470 interferon stimulated genes (ISGs), chemokines, cytotoxic proteins, and markers of
471 epithelial damage (Arunachalam et al., 2020; Filbin et al., 2021; Gisby et al., 2021).
472 More severe disease is associated with increased concentrations of inflammatory
473 proteins such as IL-6, TNF, GM-CSF, IL-1RN and IL-18 (Arunachalam et al., 2020;
474 Filbin et al., 2021; Thwaites et al., 2021). A similar pattern of upregulated proteins,
475 especially chemokines like CXCL10 and cytokines such as IL-6, is seen in the
476 airways during acute COVID19 (Liao et al., 2020; Saris et al., 2021; Szabo et al.,
477 2021). Here, we show that 3 to 6 months after SARS-CoV-2 infection, despite the
478 presence of ongoing respiratory morbidity, the majority of the plasma proteins
479 differentially expressed during acute disease appear to have returned to similar
480 concentrations to those seen in healthy controls, and even data dimension reduction
481 approaches such as WGCNA fail to highlight any significant associations between
482 COVID19 infection and the plasma proteome months later.

483

484 In contrast, the post-COVID19 airways continue to display an abnormal proteome.
485 This displayed both shared and distinct features to that seen in acute disease.
486 Proteins linked to inflammation featured less prominently than in acute COVID19;
487 instead, we observed airway upregulation of proteins involved in epithelial damage
488 and repair (e.g. the EGFR ligand AREG and the epithelial marker KRT19). Matrix
489 metalloproteinase-3 (MMP-3), which regulates the extracellular matrix (ECM), was
490 also differentially upregulated in the post-COVID19 airway. MMP3 and AREG are

Immune-proteome landscape post-COVID19

491 both upregulated after influenza A virus (IAV) infection *in vivo* in mice, and *in vitro* in
492 human fibroblasts and epithelial cells (Boyd et al., 2020); and these proteins are both
493 linked to epithelial repair and fibrosis in the lungs e.g. (Morimoto et al., 2018;
494 Yamashita et al., 2011).

495

496 The elevated concentrations of both lactate dehydrogenase and albumin in the
497 airways provide further evidence of ongoing cell death and damage to the barrier
498 integrity within the respiratory tract post-COVID19. This observation is reinforced by
499 the upregulation of a module of proteins in the BAL of post-COVID19 patients whose
500 individual members link epithelial damage (EPCAM, KRT19), cell death (CASP3) and
501 epithelial repair (TGFA), but also suggest a connection between these processes and
502 factors involved immune cell recruitment and survival (CXCL9, CXC10, CXCL11, IL-
503 7). These markers of ongoing damage and repair tightly correlate with the frequency
504 of T cells, especially CD8 TRM in the airways. In mouse models of severe acute
505 respiratory virus infection CD8 T cells have long been known to act as a double-
506 edged sword. Although the cytotoxic molecules and cytokines they release are
507 essential for clearing virus, they can also cause tissue damage and immune
508 pathology (reviewed in (Duan and Thomas, 2016; Schmidt and Varga, 2018)). While
509 the presence of pre-existing virus specific CD8 TRM in the airways is thought to be
510 highly protective against a re-encounter with the same virus in both mice and man
511 (Jozwik et al., 2015; Wu et al., 2014) almost nothing is known regarding their role in
512 long-term respiratory viral pathology, especially in humans. This is primarily due to
513 the lack of relevant samples collected during the recovery period. However, the data
514 shown here for SARS-CoV-2 may provide a potential insight, supporting the concept
515 that sustained activation of CD8 TRM in the airways, long after recovery from acute
516 disease, may contribute to ongoing immune pathology through sustained damage to
517 the respiratory epithelium.

518

519 The mechanism behind the increased number of CD8 TRM in the airways is unclear,
520 although another study has also reported detecting virus specific CD8 T cells in lung
521 tissue up to a year post-infection (Grau-Exposito et al., 2021). Both virus specific
522 CD4 and CD8 T cells rapidly expand in the circulation and airways of patients
523 following SARS-CoV-2 infection, leading to the formation of TRM (Szabo et al.,
524 2021). The majority of these activated effector T cells rapidly contract after resolution
525 of acute disease. In mice Slutter *et al* have shown that lung CD8 TRM are more
526 apoptotic than CD4 TRM after IAV infection, resulting in a more rapid decline in their
527 number. They also observed that the lungs of a mouse that had previously

Immune-proteome landscape post-COVID19

528 experienced IAV infection more robustly maintained CD8 TRM compared to an
529 uninfected lung, showing that severe infection promotes a pro-TRM niche (Slutter et
530 al., 2017). This fits with our observation that while CD8 TRM numbers dynamically
531 change dependent on the concentration of damage and proteins in the airways, and
532 indeed longitudinally in the same individuals, CD4 TRM remain relatively static. A
533 number of factors likely contribute to the heterogeneity of the CD8 TRM niche in the
534 post-COVID19 airway. Firstly, while all our post-COVID19 samples were taken from
535 patients who tested negative for SARS-CoV-2 by qPCR immediately prior to
536 bronchoscopy, persistent antigen has been observed months after other respiratory
537 infections such as IAV (Kim et al., 2010), and antigen depots in SARS-CoV-2 could
538 drive ongoing cytotoxic activity and maintenance of CD8 TRM. Secondly, the
539 persistence of lung resident TRM is also reliant on the availability of local T cell
540 survival signals such as IL-7 (Szabo et al., 2019) and the CXCR3 ligands, which are
541 known to be involved in airway recruitment and retention of CD8 memory T cells in
542 murine IAV infection (Slutter et al., 2013). We found that both IL-7 and the CXCR3
543 ligands are part of the protein network that is maintained in the post-COVID19
544 airway. These proteins display a heterogeneous pattern of upregulation across post-
545 COVID19 patient samples (**Figure 3B**) and correlate with airway T cells and CD8a
546 concentrations. Lastly there is also some evidence of ongoing aberrant inflammation
547 after acute infection and the development of autoantibodies in some patients recently
548 recovered from COVID19 (Lucas et al., 2020; Wang et al., 2020). It is likely that
549 these different mechanisms act in concert to shape the number and function of CD8
550 TRM, and other immune cells, in the post-COVID19 airway, and the scale and
551 duration of ongoing epithelial damage and respiratory pathology observed.

552

553 One factor that does not appear to influence ongoing T cell recruitment and damage
554 in the post-COVID19 airway is the activation status of the myeloid compartment, in
555 particular monocytes. Functional impairment of monocytes and DCs in the peripheral
556 blood of acutely infected patients (Arunachalam et al., 2020; Laing et al., 2020; Mann
557 et al., 2020), and hyperactivation of airway monocyte populations, are canonical
558 features of severe acute SARS-CoV-2 (Liao et al., 2020; Szabo et al., 2021).
559 Moreover, early T cell phenotypes have been strongly linked to the status of these
560 monocytes (Filbin et al., 2021; Laing et al., 2020; Szabo et al., 2021). In our post-
561 COVID19 patients, however, the monocyte and myeloid pools in both the airways
562 and peripheral blood appear to have returned to relatively normal numbers and their
563 frequency does not correlate with indicators of ongoing epithelial damage. Likewise,
564 their activation status, as determined by HLA-DR and CD86 expression, is not

Immune-proteome landscape post-COVID19

565 substantially different between individuals in line with other reports on circulating
566 monocytes from earlier stages of convalescence (Scott et al., 2020).

567

568 The airway monocyte frequency is, however, one of the few features to correlate with
569 a clinical biomarker of severity in acute disease, serum ferritin. High serum ferritin is
570 a prognostic marker used at presentation with acute COVID19 and linked to more
571 severe acute radiological findings (Carubbi et al., 2021; Ruan et al., 2020). Ferritin,
572 and transferrin, the protein responsible for transporting ferritin, are core components
573 of iron metabolism, and their dysregulation is associated with a range of lung
574 pathologies including decreased lung function and lung fibrosis (Ali et al., 2020; Lee
575 et al., 2020). In the respiratory tract the expression of CD71, the receptor that
576 scavenges transferrin from the environment, on alveolar macrophages is altered in
577 chronic respiratory disease (Striz et al., 1993), and the presence of CD71⁺ alveolar
578 macrophages, possessing both an immature and pro-fibrotic transcriptional
579 signature, has been linked to pulmonary fibrosis (Allden et al., 2019). In humans,
580 monocytes are recruited to the airways to differentiate into new AMs (Byrne et al.,
581 2020), and acute ferritin could be acting as a biomarker of severity of disruption to
582 AMs. This link is however challenging to elucidate, and it is possible that ferritin is
583 simply a proxy for the strength of the acute inflammatory response.

584

585 To our knowledge, this is the first study exploring the airway immune and proteomic
586 profiles in COVID19 patients between 3 months and 1 year post discharge from
587 hospital, and their links to ongoing respiratory pathology. Moreover, it is one of the
588 first studies to explore the human airway immune-proteome landscape after a
589 substantial period of time following any severe respiratory virus infection. Since all
590 samples were obtained more than 3 months post hospital discharge, when one might
591 expect normalization of the immune profile, the persistent immune abnormalities offer
592 possible explanations into the longevity of persistent respiratory morbidity post
593 SARS-CoV2 infection. In addition, these findings may be relevant to those suffering
594 long-term sequelae during convalescence from other viral pneumonias where data
595 are currently very limited.

596

597 We highlight a number of potential limitations of our study. Firstly, our data showing
598 immunological and proteomic changes in the BAL of post-COVID19 are generated on
599 patients undergoing clinically indicated bronchoscopy because of persistent
600 respiratory abnormalities. Whether our findings extend to individuals with no
601 radiological abnormalities or respiratory symptoms post-COVID19 remains unknown.

Immune-proteome landscape post-COVID19

602 This selection bias also affects longitudinal sampling greater than 12 months post-
603 COVID19, since the majority of patients initially sampled between 3-6 months post-
604 COVID19 had shown sufficient improvement in respiratory pathology such that a
605 follow-up bronchoscopy was not indicated. The progressive resolution of radiological
606 abnormalities in the majority of post-COVID19 patients has been observed by others
607 (Han et al., 2021), and importantly within our study even the 3 patients with ongoing
608 pathology have a significantly improved CT and reduced immune cell infiltration
609 within their airways. This fits with the hypothesis that SARS-CoV2 infection can result
610 in organizing pneumonia, with subsequent changes reflecting ongoing epithelial
611 damage and healing parenchyma rather than established fibrosis (Kory and Kanne,
612 2020). This is both compatible with autopsy findings during the acute disease
613 (Wichmann et al., 2020) and the steroid-responsive nature of the acute pathology
614 (Horby et al., 2021).

615

616 Although we did not detect a plasma proteomic signature post-COVID19, this is likely
617 due to our limited sample size not being powered to detect small differences in
618 circulating proteins between post-COVID19 patients and healthy controls.
619 Examination of the distributions of p-values suggests that such differences may exist
620 (**Figure S3**) but will likely require future much larger cohort studies to reveal them.
621 Regardless, the absence of any correlation between the differentially expressed
622 proteins in the airways and their corresponding changes in the plasma points to the
623 limited utility of peripheral blood as an indicator of the pathological processes
624 ongoing in the lung.

625

626 Finally, as with most studies, we were limited to sampling the airways post-infection
627 and so did not have paired pre-infection samples for intra-individual comparisons.
628 Therefore, it is possible that some differences observed between healthy controls
629 and post-COVID19 patients could reflect a pre-infection phenotype that predisposed
630 them to developing prolonged sequelae. Indeed, one of the most differentially
631 expressed proteins in the airways, DPP4, is the binding receptor for another
632 coronavirus MERS (Raj et al., 2013), and postulated to be capable of mediating
633 some SARS-CoV-2 binding (Li et al., 2020). Thus, it is conceivable that pre-existing
634 upregulation of DPP4 increased susceptibility to post-COVID19 syndrome via
635 increased viral entry (i.e. reverse causation), rather than DPP4 upregulation
636 occurring in response to COVID19. However, the longitudinal reduction of DPP4
637 argues against this hypothesis. More generally, the majority of proteins and markers
638 upregulated are associated with ongoing lung pathology in other contexts (e.g. LDH),

Immune-proteome landscape post-COVID19

639 and are absent or only present at very low concentrations in the healthy airway,
640 suggesting that their upregulation is more likely to be a consequence of COVID19
641 than a pre-disposing risk factor.

642

643 In summary, our study offers unique and novel insights into ongoing
644 immunopathology post-COVID19. In contrast to the inflammatory pathways observed
645 during acute disease, we found proteins associated with ongoing epithelial damage,
646 cell death, and repair were upregulated in conjunction with ongoing CD8 T cell
647 activation. These data indicate that significant immune pathways operate within the
648 tissue, presumably to facilitate repair and resolution, even in the absence of
649 peripheral inflammation. In the future it will be important to determine how such a
650 substantial shift in the immune landscape of the airways might affect the response to
651 a subsequent respiratory infection such as seasonal influenza. The progressive
652 improvement in respiratory pathology, even in this cohort with substantive
653 radiological abnormalities should be seen as a positive indicator for the long-term
654 prognosis for those with persistent morbidity. Moreover, the involvement of the
655 immune response suggests this recovery could be accelerated using immuno-
656 modulatory treatments, especially those designed against TH1 immune responses.

657

Immune-proteome landscape post-COVID19

658 **Funding**

659 This work was supported by a Wellcome Trust Senior Fellowship 107059/Z/15/Z to
660 C.M.L., a Rosetrees Seed Fund to P.L.M. and J.A.H. (A2172) and an Imperial
661 College Healthcare NHS Trust BRC award to J.A.H. (RDF04). B.V. is funded by the
662 Joint Research Committee on behalf of a joint collaboration between CW+ and
663 Westminster Medical School Research Trust. K.B. is funded by an Asthma UK PhD
664 Studentship as part of the Asthma UK centre in allergic mechanisms of asthma
665 (AUK-BC-2015-01). R.J.S. is supported by a Wellcome Trust Senior Fellowship
666 (209458/Z/17/Z). J.E.P. is supported by a UKRI COVID19 Rapid Response Rolling
667 Call (MR/V027638/1), the Imperial College London Community Jameel and the
668 Imperial President's Excellence Fund, and a UKRI Innovation Fellowship at Health
669 Data Research UK (MR/S004068/2).

670

671 **Acknowledgements**

672 We thank Jack Gisby for statistical and analytical advice and Simone Walker for
673 technical assistance. We also thank the staff of Sir Alexander Fleming Building Flow
674 Cytometry Facility at Imperial College London for assistance with flow acquisition and
675 analysis. The schematic in Figure 1A was made using Biorender. We also thank Dr
676 Ryan Thwaites and Professor Peter Openshaw, Imperial College London, for
677 critically reading this manuscript before submission.

678

679 **Author contributions:**

680 **BV** and **PLS** designed the PHENOTYPE study and were involved in recruitment of
681 the post-COVID19 cohort. **PLS**, **CML**, **JEP** and **JAH** designed and conceived the
682 current study. **JAH** and **CML** co-ordinated the study. **BV**, **JT**, **CO**, **JG** and **PLS**
683 collected clinical samples and patient information for the post-COVID19 cohort. **RJH**
684 and **PLM** designed and were responsible for recruitment and sampling of the healthy
685 control cohort. **BV**, **KB** and **PPO** processed clinical samples for the post-COVID19
686 cohort. **PG** processed clinical samples for the healthy control cohort. **BV**, **KB**, **PPO**
687 and **PG** conducted flow cytometry and mediator measurements. **KS** measured LDH
688 and albumin. **KB** and **PPO** analysed the flow cytometry analysis. **AP** analyzed the
689 Olink proteomics data set. **PS** supervised the clinical aspects of the project, **JEP**
690 supervised the bioinformatic analysis. **RJS**, **PLM**, **CML** and **JAH** supervised the
691 laboratory preparation of samples and flow cytometry and mediator measurement
692 analysis. **BV**, **KB**, **PPO**, **AP**, **JEP**, **PLS**, **CML** and **JAH** were involved in data
693 interpretation. **JAH** wrote the initial draft of the manuscript and **BV**, **KB**, **PPO**, **AP**,
694 **JEP**, **PLS** and **CML** carried out major writing of the paper. All the authors reviewed

Immune-proteome landscape post-COVID19

695 and approved the submitted manuscript. For information on proteomics contact
696 James E Peters, j.peters@imperial.ac.uk; For clinical information contact Pallav L
697 Shah, pallav.shah@imperial.ac.uk; For epithelial cell biology and repair contact Clare
698 M Lloyd, c.lloyd@imperial.ac.uk; For immune cell phenotyping contact James A
699 Harker, j.harker@imperial.ac.uk.
700

Immune-proteome landscape post-COVID19

701 **Figure legends**

702

703 **Figure 1: Increased airway lymphocytes in the 3 to 6 months post COVID-19**

704 **(A)** Schematic of study design. BAL and blood were sampled from healthy donors
705 and at > 80 days after hospital discharge from post-COVID19 patients. Traditional
706 and spectral flow cytometry and Olink proteomics was performed on BAL and plasma
707 and correlated with clinical parameters. **(B)** Left: Total number of cells in BAL from
708 healthy controls and post-COVID19 patients. Right: total number of cells in BAL from
709 post-COVID19 patients, stratified according to severity of the acute illness. **(C)** Total
710 cell numbers of immune populations ($\times 10^6$ /ml) in BAL from healthy controls and post-
711 COVID19 patients, based on gating shown in Methods Figure 1.

712 Data are presented as mean \pm SEM. Healthy controls n = 16, post-COVID19 patients
713 n = 21, moderate n = 6, severe n = 8, very severe n = 7. Statistical significance was
714 tested by Mann Whitney U test or Kruskal Wallis test + Dunn's multiple comparison
715 test. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.

716

717 **Figure 2: A distinct proteome is present in the post COVID-19 airway**

718 436 proteins in BAL and plasma 435 proteins were measured using Olink
719 immunoassays in post-COVID19 patients (n = 19) and healthy controls (n = 9). **(A)**
720 Principal component analysis (PCA) of BAL and plasma proteomes: each point
721 represents a sample. **(B)** Left: heatmap displaying Z-score normalised protein
722 abundance for the 22 proteins that were significantly differentially abundant (5%
723 FDR) between post-COVID19 and healthy controls in BAL. Samples have been
724 ordered by case control status and then by peak severity during acute COVID-19
725 infection. Proteins are ordered by hierarchical clustering. Right: heatmap for these
726 same 22 proteins in plasma, presented in the same order as for BAL. **(C)** Volcano
727 plot showing differentially protein abundance analysis between post-COVID19
728 patients and healthy controls in BAL. Nominal $-\log_{10}$ P values are shown.
729 Significantly differentially abundant proteins (5% FDR) are coloured in red and
730 labelled. **(D)** BAL and plasma normalised protein abundance (NPX) expression for
731 the 5 most significantly differentially abundance proteins between post-COVID19
732 patients and healthy controls. P_{BH} = Benjamini-Hochberg adjusted p-values. **(E)**
733 Correlation between the 22 differentially abundant proteins and immune cell
734 frequency in BAL.

735

Immune-proteome landscape post-COVID19

736 **Figure 3: A network of proteins linked to immune cell chemotaxis and cell** 737 **death is upregulated in the BAL post-COVID19**

738 WGCNA of BAL proteome of post-COVID19 patients and healthy controls. **(A)**
739 Associations of protein modules identified by WGCNA with case-control status (post-
740 COVID19 or healthy). **(B)** Heatmap displaying Z-score normalised protein abundance
741 for the 37 proteins that form the 'red' protein module. Samples are ordered according
742 to clinical status. Severity refers to peak severity of the acute COVID19 episode.
743 Proteins are ordered by hierarchical clustering. **(C)** Right: Network representation of
744 proteins in the red module and their interconnections defined using String-db. An
745 edge in the network represents a relationship between proteins, coloured according
746 to the type of evidence for the connection (see Methods). Left: list of hub proteins
747 within the network (with hub proteins that were also significantly differentially
748 upregulated in post-COVID19 patient BAL highlighted in red).

749

750 **Figure 4. CXCR3 ligands and markers of epithelial damage correlate with CD8 T** 751 **cells in the airways**

752 BAL immune cells and protein concentrations were analysed post-COVID19
753 infection. **(A)** Linear regression analysis was conducted between $n = 435$ proteins
754 measured in the BAL using the Olink platform and BAL immune cell frequencies
755 identified by flow cytometry as shown in Figure 1. A heatmap showing proteins with
756 the highest correlation versus 5 major immune cell frequencies is shown. **(B-C)** For
757 each sample, protein levels for CXCL9, -10 and -11, were normalised to the median
758 level in healthy controls. For each sample, the mean of the normalised values for the
759 3 proteins was calculated to provide a summary metric for CXCR3 chemokines. This
760 was then plotted against versus **(B)** T, NK and NKT proportions in post-COVID19
761 patients and healthy controls and **(C)** monocyte frequencies and subsets in post-
762 COVID19 patients only. **(D)** BAL T cell frequency versus CD4 and CD8a
763 concentrations as measured by Olink. **(E)** CD8a concentration versus CASP3,
764 EPCAM, MB and DPP4 in the airways. **(F)** DPP4, albumin and LDH concentrations in
765 the BAL determined by ELISA. Data are presented as median \pm IQR. **(A)** Pearsons
766 correlation of $n = 19$ post-COVID19 patients, the r value is shown. **(B-E)** Each point
767 represents an individual patient, linear regression line \pm 95% confidence intervals
768 are depicted, and r and p values from Pearsons correlation are stated. **(F)** represents
769 $n = 38$ post-COVID19 and $n = 20$ healthy control individuals. Statistics were
770 conducted using Mann-Whitney U test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.005$, **** $P <$
771 0.001 . pCOVID = post-COVID19.

772

Immune-proteome landscape post-COVID19

773 **Figure 5. Myeloid cell frequencies are not linked to indications of ongoing** 774 **damage in the post-COVID19 airway**

775 BAL and blood immune cells from post-COVID19 patients were analyzed by spectral
776 deconvolution cytometry. **(A)** Heatmap of normalised median expression of myeloid
777 cell modulatory and subset markers by clusters of myeloid cells in the airways
778 identified by FlowSOM analysis. **(B)** Violin plot showing frequencies of each cluster in
779 BAL and blood. **(C)** Violin plots showing classical, non-classical and intermediate
780 monocyte subsets as proportions of live leukocytes in BAL and blood identified by
781 manual gating. **(D)** Violin plots showing pDC, cDC1 and cDC2 cell proportions in BAL
782 and blood. **(E)** Geometric mean fluorescence intensity of activation markers
783 expressed by CD11c⁺ monocytes. **(F)** Pearson's correlation between BAL myeloid
784 subsets (as a % of leukocytes) and airway LDH, albumin and DPP4. Data are
785 presented as median ± IQR. Each point represents an individual patient. Statistical
786 significance for **(B)**, **(C)** and **(D)** was tested by Mann-Whitney U test. *P < 0.05, **P <
787 0.01, ***P < 0.005, ****P < 0.001.

788

789 **Figure 6. The airways of post-COVID19 patients are enriched for activated CD8** 790 **TRM cells**

791 BAL and blood immune cells from post-COVID19 patients were analyzed by spectral
792 deconvolution cytometry. **(A)** Heatmap of normalised median expression of T cell
793 modulatory and subset markers by clusters of T cells in the airways identified by
794 FlowSOM analysis. **(B)** Violin plot showing frequencies of each cluster in BAL and
795 blood. **(C)** tSNE projection of clusters identified by FlowSOM analysis in BAL and
796 blood. **(D)** Violin plots showing CD4⁺ and CD8⁺ T cell subsets as proportions of all T
797 cells in BAL and blood identified by manual gating. **(E)** Violin plots showing gd, NK,
798 NKT and MAIT cell proportions in BAL and blood. **(F)** Pearson correlations between
799 total airway CD4⁺ and CD8⁺ T cell numbers and subsets. **(G)** Heatmap depicting
800 Pearson correlation between different T cell populations (as a % of BAL leukocytes)
801 and the concentration of DPP4, LDH and Albumin in the airways. **(F)** Pearson
802 correlations between the gMFI of LDH and albumin. Data are presented as median ±
803 IQR. Each point represents an individual patient. **(A, B, E and F)** represent n = 20
804 individuals. **(C)** represents an equal number of cells from n = 10 patients combined.
805 **(G & H)** represents n = 18 individuals. Statistical significance for **(B)**, **(D)**, **(E)** and **(G)**
806 was tested by Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.005, ****P <
807 0.001.

808

Immune-proteome landscape post-COVID19

809 **Figure 7. Reduced cellularity in the airways one year after initial bronchoscopy**
810 **post-COVID19**

811 **(A)** Total cell counts (left) and proportions of lymphocytes (right) in the BAL following
812 first bronchoscopy and one year follow-up bronchoscopy. **(B)** Cell counts of
813 lymphocyte populations in the BAL following first bronchoscopy and one year follow-
814 up bronchoscopy. **(C)** Cell counts of myeloid populations in the BAL following first
815 bronchoscopy and one year follow-up bronchoscopy. **(D)** Proportions of T cell
816 subsets in the BAL following first bronchoscopy and one year follow-up
817 bronchoscopy. **(E)** LDH (left) and albumin (right) measurements in BAL following first
818 year bronchoscopy and one year follow-up bronchoscopy. **(F)** Percentage of
819 abnormal CT following first year CT and one year follow-up CT. **(G)** BAL LDH and
820 albumin quantification following first year bronchoscopy and one year follow-up
821 bronchoscopy. Each point represents a single patient. Green shading indicates
822 median \pm IQR for proportions of populations and mediator levels observed in healthy
823 airways.

824
825

Immune-proteome landscape post-COVID19

826 **Methods**

827 **Post-COVID-19 patient recruitment**

828 Post-COVID19 bronchoalveolar lavage fluid (BAL) was obtained from patients
829 recruited to the PHENOTYPE study (NCT 04459351), an observational, longitudinal
830 study recruiting patients at Chelsea and Westminster Hospital, London. 38 samples
831 were collected from patients requiring sampling for clinical purposes. Ethical approval
832 for the study was given by Yorkshire & The Humber - Sheffield Research Ethics
833 Committee (IRAS 284497).

834

835 Patients who met the inclusion and exclusion criteria were recruited to the
836 PHENOTYPE study:

837 Inclusion criteria for the study were:

- 838 • Aged 18 years or older
- 839 • Previous confirmed COVID-19 infection (positive PCR or antibody)
- 840 • Attending a respiratory follow-up outpatient appointment for follow-up of
841 persistent respiratory symptoms following visit post hospital attendance
842 with COVID-19 infection or referred by the community for covid-related
843 symptoms.

844

845 Patients were seen at approximately 4-6 weeks (Visit 1) and 3 months (Visit 2)
846 following discharge from hospital or referral (if referred from the community). Patients
847 underwent clinical assessment at both visits, including collection of demographic
848 data, clinical history and clinical examination and assessment of vital
849 parameters (heart rate, peripheral oxygen saturations, blood pressure reading
850 and temperature). They also underwent clinical blood tests (including full blood count,
851 renal function, liver function, C-reactive protein (CRP), ferritin, fibrinogen, D-dimer
852 and pro-calcitonin). Patients had a computed tomography (CT) scan of the lungs
853 approximately 3 months post discharge from hospital. In patients with abnormal CT
854 findings, or persistent respiratory symptoms, a bronchoscopy and lavage was
855 performed as part of clinical work-up. Patients underwent formal lung function tests
856 (including spirometry, lung volumes and gas transfer) near the time of the
857 bronchoscopy (usually during the days immediately preceding the procedure).
858 Further follow-up was determined on the basis of clinical need, with a maximum
859 follow up period of up to 2 years post hospital discharge or referral.

860

861 **Post-COVID19 bronchoalveolar lavage (BAL) sampling**

Immune-proteome landscape post-COVID19

862 Bronchoscopy was performed under conscious or deep sedation. 150 ml of normal
863 saline were instilled into the most affected segment (as determined by CT imaging),
864 in 50 ml aliquots. 10 ml of fluid return was used for the scientific analysis described in
865 this paper.

866

867 **Healthy volunteer recruitment and sampling**

868 Control, uninfected bronchoalveolar lavage was obtained from healthy donors
869 (collected between April 2016 and December 2019). Ethical approval for the study
870 was granted by the Research Ethics Committee (15/SC/0101) and all patients
871 provided informed written consent as described previously (Allden et al., 2019; Byrne
872 et al., 2020; Invernizzi et al., 2021). Briefly, 240 ml aliquots of warmed sterile saline
873 were instilled in the right middle lung and aspirated by syringe. Lavage aliquots were
874 pooled for each subject. All subjects provided written, informed consent to participate
875 in the study. Healthy volunteers had no self-reported history of lung disease, an
876 absence of infection within the last 6 months and normal spirometry.

877

878 **BAL processing**

879 BAL samples were processed and stained on the day of sample collection. BAL was
880 strained through a 70µm filter and subsequently centrifuged (1800 rpm, 2 min, 4°C).
881 Supernatant was snap-frozen and stored at -80°C. Pellets were incubated in red
882 blood cell lysis buffer (155mM NH₄Cl, 10mM KHCO₃, 0.1mM
883 ethylenediaminetetraacetic acid, pH 7.4) for 10 minutes before washing and
884 resuspension in complete media (RPMI 1640 with 10% fetal calf serum, 2mM L-
885 glutamine, 100U/ml penicillin-streptomycin).

886

887 **Blood processing**

888 Peripheral blood was collected in EDTA coated vacutainers on the same day as
889 bronchoscopy. 1ml blood was centrifuged at 100g for 10 minutes (4°C), followed by
890 centrifugation at 20,000g for 20 minutes (4°C) to separate plasma, which was
891 subsequently stored at -80°C. 2ml blood from post COVID-19 patients was incubated
892 with red blood cell lysis buffer (155mM NH₄Cl, 10mM KHCO₃, 0.1mM
893 ethylenediaminetetraacetic acid, pH 7.4) for 10 minutes before washing and
894 resuspension in complete media (RPMI 1640 with 10% fetal calf serum, 2mM L-
895 glutamine, 100U/ml penicillin-streptomycin). 2.5 ml blood from healthy controls was
896 used to isolate peripheral blood mononuclear cells (PBMC) by Percoll density
897 centrifugation, as per manufacturer's instructions.

Immune-proteome landscape post-COVID19

898

899 **Flow cytometry staining**

900 For traditional flow cytometry, 2 - 5 x10⁵ cells were plated, while for high parameter
901 analysis using the Cytex Aurora 1 x 10⁶ cells from each site were used. Cells were
902 washed with PBS and incubated with either near-infrared (traditional flow cytometry)
903 or blue (Cytex Aurora) fixable live/dead stain (Life Technologies), as per the
904 manufacturer's instructions. Before incubation with human fc block (BD Pharmingen)
905 cells were washed with FACS buffer (1% FCS, 2.5% HEPES, 1mM EDTA) and
906 surface staining was performed at 4°C for 30 minutes using antibody panels as
907 described in the **Key Resources Table**. Surface staining was followed by washing
908 with FACS buffer and fixation with 1% paraformaldehyde for 10 minutes. Labelled
909 cells were acquired on a 4-laser BD Fortessa (traditional flow cytometry; BD
910 Bioscience) or 5-laser Cytex Aurora flow cytometer (Cytex Bio).

911

912 **Flow cytometry analysis**

913 Conventional flow cytometry data was analysed using FlowJo v 10.6 (Tree Star).
914 Data was pre-gated to exclude doublets and dead cells. In BAL samples CD45⁺ cells
915 were selected, and immune cell populations were identified using the gating strategy
916 shown in **Methods Figure 1**. Percentages of the CD45⁺ gate were calculated. In
917 blood samples, leukocytes were selected based on FSC and SSC and immune cell
918 populations were identified using the gating strategy shown in **Methods Figure 1**.
919 Percentages of total leukocytes were calculated. High-parameter spectral
920 deconvolution flow cytometry data from the Cytex Aurora was analysed using
921 Cytobank (Beckman). tSNE analysis was performed on 300,000 events from 11 files.
922 Iteration number was set to 1500 with a perplexity of 30 and theta of 0.5. FlowSOM
923 analysis was performed subsequently using hierarchical consensus clustering with
924 12 metaclusters, 100 clusters and 10 iterations. Manual gating of high parameter
925 cytometry data was carried out as shown in **Methods Figure 2**. Heatmaps were
926 generated from median fluorescence values in Prism 9.0 (GraphPad).

927

928 **Quantification and statistical analysis for flow cytometry**

929 Differences in means between two sample groups were compared using two-tailed
930 Mann-Whitney U tests. Multiple group comparisons were done using Kruskal Wallis
931 ANOVA followed by Dunn's post-test. Spearman-Rank correlations were used to
932 correlate clinical blood parameters with immune cell populations. Analysis was
933 performed in GraphPad Prism. For all figures, * denotes p value < 0.05, ** denotes p
934 value < 0.01 and *** denotes p value < 0.001.

Immune-proteome landscape post-COVID19

935

936 **Proteomic assays**

937 Plasma and BAL proteomic measurement was performed using the Olink proximity
938 extension immunoassay platform. Five 92-protein multiplex Olink panels were used
939 ('Inflammation', 'Immune Response', 'Cardiometabolic', Cardiovascular 2',
940 'Cardiovascular 3'), providing measurements of 460 protein targets per sample.
941 Cryopreserved BAL and plasma samples were thawed on ice and mixed well by
942 pipetting before plating 88 samples per plate ensuring case/control balance and
943 random well ordering to prevent confounding of technical and biological effects. For
944 BAL samples, a pilot study was performed using three control samples and three
945 post-COVID19 samples (severe group) to determine optimal dilution parameters.
946 Ultimately BAL was used neat. Since a small number of proteins were assayed on
947 more than one panel, we measured a total of 435 unique proteins. We removed
948 duplicate assays at random prior to subsequent analyses.

949

950 **Proteomics analyses**

951 Proteomic data was normalised using standard Olink workflows to produce relative
952 protein abundance on a log₂ scale ('NPX'). BAL and plasma proteomic data were
953 normalised separately. Quality assessment was performed by (1) examination of
954 Olink internal controls and (2) inspection of boxplots, relative log expression plots,
955 and PCA.

956 PCA was performed using singular value decomposition. Following these steps, 2
957 clear outlying samples were removed from the BAL dataset.

958

959 To identify proteins that were differentially abundant between case and controls, for
960 each protein we performed linear regression (lm function in R) with case/control
961 status as the independent variable and protein level (NPX) as the dependent
962 variable. P-values were adjusted for multiple testing using the Benjamini-Hochberg
963 procedure (p.adjust function in R). A 5% false discovery rate was used to define
964 statistical significance.

965

966 We used the WGCNA R package (Langfelder and Horvath, 2008; Zhang and
967 Horvath, 2005) to create a weighted protein correlation network. Prior to WGCNA
968 analysis, protein data were scaled and centred, and missing data were imputed using
969 the R caret package. We used the WGCNA adjacency function to produce a weighed
970 network adjacency matrix, using parameters "type=signed" and "power=13". This
971 soft-thresholding power was selected as the lowest power to achieve approximate

Immune-proteome landscape post-COVID19

972 scale-free topology. We next defined a topological overlap matrix of dissimilarity
973 using the TOMdist function. Clusters ('modules') of interconnected proteins were
974 identified using hierarchical clustering and the cutreeDynamic function with
975 parameters: method="hybrid", deepSplit=2, minClusterSize=15. We then tested
976 association of these modules with case/control status. Multiple testing correction was
977 performed to account for the number of modules. We report both Benjamini-
978 Hochberg and Bonferroni adjusted p-values to provide two levels of stringency.

979

980 To assess the distribution of p-values from the differential protein abundance
981 analyses, we plotted histograms and constructed QQ plots. QQ plots were made by
982 comparing the expected distribution of $-\log_{10} P$ values under the null hypothesis of
983 no proteomic differences between post-COVID19 patients and controls to the
984 observed p-values for the 435 proteins.

985

986 We performed pathway enrichment analysis for the 435 proteins measured. This was
987 performed using terms from KEGG database (**Supplementary File 1B**) and the
988 Reactome database (**Supplementary File 1C**).

989

990 Protein modules were visualised using STRING (<https://string-db.org/>), with known or
991 suspected interconnections between module members displayed as edges in a
992 network diagram. An edge represents a protein-to-protein relationship defined as
993 shared contributions to a particular function, and not necessarily implying physical
994 binding. In **Figure 3C**, edge colour indicates the type of evidence for the relationship:
995 turquoise represents known interactions from curated databases; magenta
996 represents experimentally determined interactions; green represents predicted
997 Interactions from gene neighbourhood analysis; red represent predicted interactions
998 from gene fusions, blue represent predicted Interactions from gene co-occurrence;
999 light green represents interaction from text-mining; black represents interaction from
1000 co-expression data, and violet represents information from protein homology.

1001

1002 **CXCR3 chemokine composite score**

1003 To create a composite score that reflected the CXCR3 chemokines (CXCL9,
1004 CXCL10 and CXCL11), we used the following approach. For each sample, protein
1005 levels for CXCL9, -10 and -11, were normalised to the median level in healthy
1006 controls (to avoid unduly weighting the score towards chemokines with higher NPX
1007 values). For each sample, the mean of the normalised values for the 3 proteins was
1008 then calculated to provide a summary metric for CXCR3 chemokines.

Immune-proteome landscape post-COVID19

1009

1010

1011 **Quantification of mediators in BAL**

1012 DPP4 (R&D systems, DY1180) and albumin (Bethyl Laboratories, E80-129)
1013 concentrations in the BAL were quantified by ELISA according to manufacturer's
1014 instructions. LDH concentrations were quantified using an *in vitro* toxicology assay
1015 (Sigma, TOX7). Briefly, 25µl of BAL sample were incubated with 50µl of LDH assay
1016 reaction mixture. After 30 minutes, the reaction was stopped with 7.5µl 1N HCL and
1017 absorbance was measured at 490nm with background correction at 690nm. All
1018 absorbances were measured using a SpectraMax i3x (Molecular Devices).

1019

1020 **Key Resources Table**

Reagent or Resource	Source	Identifier	Dilution
Antibodies			
Anti-Human CD69, BUV395	BD Biosciences	564364	1:20
Anti-human CD8, BUV496	BD Biosciences	612942	1:100
Anti-Human CD45RA, BUV563	BD Biosciences	612927	1:100
Anti-Human CD11c, BUV661	BD Biosciences	612968	1:100
Anti-Human CD56, BUV737	BD Biosciences	612767	1:100
Anti-Human CD3, BUV805	BD Biosciences	612896	1:100
Anti-Human IgD, BV421	Biolegend	348226	1:100
Anti-Human CD16, SuperBright436	ThermoFisher	62-0166-42	1:100
Anti-Human CD25, eFluor450	ThermoFisher	48-0257-42	1:100
Anti-Human CD20, BV480	BD Biosciences	566132	1:100
Anti-Human CD127, BV510	Biolegend	351332	1:50

Immune-proteome landscape post-COVID19

Anti-Human HLA-DR, BV570	Biologend	307638	1:100
Anti-Human CD28, BV605	Biologend	302968	1:100
Anti-Human CD38, BV650	Biologend	356620	1:100
Anti-Human CD15, BV711	Biologend	323050	1:100
Anti-Human CD279, BV750	Biologend	329966	1:100
Anti-Human CD206, BV785	Biologend	321142	1:20
Anti-Human CD45, QDOT800	ThermoFisher	Q10156	1:800
Anti-Human CXCR5, BB515	BD Biosciences	564624	1:50
Anti-Human CD169, AF488	R&D systems	FAB5197G	1:100
Anti-Human CD4, Spark Blue 550	Biologend	344656	1:100
Anti-Human CD161, PerCP	Biologend	3399334	1:20
Anti-Human CD27, BB700	BD Biosciences	566449	1:100
Anti-Human Siglec8, PerCP Cy5.5	Biologend	347108	1:100
Anti-Human CD86, PerC eFLuor710	ThermoFisher	46-0869-42	1:100
Anti-Human CD141, PE	Biologend	344104	1:20
Anti-Human TCRg/d, PEdz594	Biologend	331226	1:100
Anti-Human TCRA/b PE Cy5	Biologend	306710	1:100
Anti-Human CD11b, PE Cy7	Biologend	301322	1:100

Immune-proteome landscape post-COVID19

Anti-Human CD123, APC	Biologend	306012	1:100
Anti-Human CRTH2, AF647	Biologend	350104	1:100
Anti-Human CD14, Spark NIR	Biologend	367150	1:100
Anti-Human CD1c, APC R700	BD Biosciences	566614	1:100
Anti-Human CD103, APC Cy7	Biologend	350228	1:100
Anti-Human CD45, PerCP Cy5.5	ThermoFisher	45-0459-42	1:25
Anti-Human Siglec8, AF488	R&D systems	FAB7975G	1:100
Anti-Human CD19, BV421	Biologend	302234	1:100
Anti-Human CD4, BV510	Biologend	317444	1:100
Anti-Human CD117, BV605	Biologend	313218	1:100
Anti-Human CD14, BV711	Biologend	301838	1:100
Anti-Human CD16, BV785	Biologend	302046	1:100
Anti-Human CD177, FITC	Biologend	315804	1:100
Anti-Human Siglec8, PE	R&D systems	FAB7975P	1:100
Anti-Human CD56, PEdz594	Biologend	318348	1:100
Anti-Human CD3, PE- Cy7	Biologend	300420	1:100
Anti-Human CD206, APC	Biologend	321110	1:100
Anti-Human FcE, AF700	Biologend	334630	1:100

Immune-proteome landscape post-COVID19

LIVE/DEAD Fixable NIR Cell Stain	ThermoFisher	L34976	1:1000
LIVE/DEAD Fixable Blue? Cell Stain	ThermoFisher	L34961	1:1000
TruStain FcX	Biolegend	422302	1:100
RPMI 1640	Gibco	21875091	

1021

1022

Immune-proteome landscape post-COVID19

1023

1024

1025

Immune-proteome landscape post-COVID19

1026 References

1027

- 1028 Ali, M.K., Kim, R.Y., Brown, A.C., Donovan, C., Vanka, K.S., Mayall, J.R., Liu, G.,
1029 Pillar, A.L., Jones-Freeman, B., Xenaki, D., *et al.* (2020). Critical role for iron
1030 accumulation in the pathogenesis of fibrotic lung disease. *J Pathol* 251, 49-62.
- 1031 Allden, S.J., Ogger, P.P., Ghai, P., McErlean, P., Hewitt, R., Toshner, R., Walker,
1032 S.A., Saunders, P., Kingston, S., Molyneaux, P.L., *et al.* (2019). The Transferrin
1033 Receptor CD71 Delineates Functionally Distinct Airway Macrophage Subsets during
1034 Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 200, 209-219.
- 1035 Arunachalam, P.S., Wimmers, F., Mok, C.K.P., Perera, R., Scott, M., Hagan, T.,
1036 Sigal, N., Feng, Y., Bristow, L., Tak-Yin Tsang, O., *et al.* (2020). Systems biological
1037 assessment of immunity to mild versus severe COVID-19 infection in humans.
1038 *Science* 369, 1210-1220.
- 1039 Boyd, D.F., Allen, E.K., Randolph, A.G., Guo, X.J., Weng, Y., Sanders, C.J.,
1040 Bajracharya, R., Lee, N.K., Guy, C.S., Vogel, P., *et al.* (2020). Exuberant fibroblast
1041 activity compromises lung function via ADAMTS4. *Nature* 587, 466-471.
- 1042 Byrne, A.J., Powell, J.E., O'Sullivan, B.J., Ogger, P.P., Hoffland, A., Cook, J.,
1043 Bonner, K.L., Hewitt, R.J., Wolf, S., Ghai, P., *et al.* (2020). Dynamics of human
1044 monocytes and airway macrophages during healthy aging and after transplant. *J Exp*
1045 *Med* 217.
- 1046 Carubbi, F., Salvati, L., Alunno, A., Maggi, F., Borghi, E., Mariani, R., Mai, F.,
1047 Paoloni, M., Ferri, C., Desideri, G., *et al.* (2021). Ferritin is associated with the
1048 severity of lung involvement but not with worse prognosis in patients with COVID-19:
1049 data from two Italian COVID-19 units. *Sci Rep* 11, 4863.
- 1050 Chen, Z., and Wherry, E.J. (2020). T cell responses in patients with COVID-19. *Nat*
1051 *Rev Immunol* 20, 529-536.
- 1052 Dan, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu, E.D., Faliti, C.E., Grifoni, A.,
1053 Ramirez, S.I., Haupt, S., Frazier, A., *et al.* (2021). Immunological memory to SARS-
1054 CoV-2 assessed for up to 8 months after infection. *Science* 371.
- 1055 Docherty, A.B., Harrison, E.M., Green, C.A., Hardwick, H.E., Pius, R., Norman, L.,
1056 Holden, K.A., Read, J.M., Dondelinger, F., Carson, G., *et al.* (2020). Features of 20
1057 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical
1058 Characterisation Protocol: prospective observational cohort study. *BMJ* 369, m1985.
- 1059 Drake, T.M., Riad, A.M., Fairfield, C.J., Egan, C., Knight, S.R., Pius, R., Hardwick,
1060 H.E., Norman, L., Shaw, C.A., McLean, K.A., *et al.* (2021). Characterisation of in-
1061 hospital complications associated with COVID-19 using the ISARIC WHO Clinical
1062 Characterisation Protocol UK: a prospective, multicentre cohort study. *Lancet* 398,
1063 223-237.
- 1064 Duan, S., and Thomas, P.G. (2016). Balancing Immune Protection and Immune
1065 Pathology by CD8(+) T-Cell Responses to Influenza Infection. *Front Immunol* 7, 25.
- 1066 Fabbri, L., Moss, S., Khan, F., Chi, W., Xia, J., Robinson, K., Smyth, A., Jenkins, G.,
1067 and Stewart, I. (2021). Post-viral parenchymal lung disease of COVID-19 and viral
1068 pneumonitis: A systematic review and meta-analysis. *medRxiv*,
1069 2021.2003.2015.21253593.
- 1070 Filbin, M.R., Mehta, A., Schneider, A.M., Kays, K.R., Guess, J.R., Gentili, M.,
1071 Fenyves, B.G., Charland, N.C., Gonye, A.L.K., Gushterova, I., *et al.* (2021).
1072 Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated
1073 signatures, tissue-specific cell death, and cell-cell interactions. *Cell Rep Med* 2,
1074 100287.
- 1075 Gisby, J., Clarke, C.L., Medjeral-Thomas, N., Malik, T.H., Papadaki, A., Mortimer,
1076 P.M., Buang, N.B., Lewis, S., Pereira, M., Toulza, F., *et al.* (2021). Longitudinal
1077 proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and
1078 predictors of death. *Elife* 10.

Immune-proteome landscape post-COVID19

- 1079 Grau-Exposito, J., Sanchez-Gaona, N., Massana, N., Suppi, M., Astorga-Gamaza,
1080 A., Perea, D., Rosado, J., Falco, A., Kirkegaard, C., Torrella, A., *et al.* (2021).
1081 Peripheral and lung resident memory T cell responses against SARS-CoV-2. *Nat*
1082 *Commun* 12, 3010.
- 1083 Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei,
1084 C.L., Hui, D.S.C., *et al.* (2020). Clinical Characteristics of Coronavirus Disease 2019
1085 in China. *N Engl J Med* 382, 1708-1720.
- 1086 Guler, S.A., Ebner, L., Aubry-Beigelman, C., Bridevaux, P.O., Brutsche, M.,
1087 Clarenbach, C., Garzoni, C., Geiser, T.K., Lenoir, A., Mancinetti, M., *et al.* (2021).
1088 Pulmonary function and radiological features 4 months after COVID-19: first results
1089 from the national prospective observational Swiss COVID-19 lung study. *Eur Respir J*
1090 57.
- 1091 Han, X., Fan, Y., Alwalid, O., Li, N., Jia, X., Yuan, M., Li, Y., Cao, Y., Gu, J., Wu, H.,
1092 and Shi, H. (2021). Six-month Follow-up Chest CT Findings after Severe COVID-19
1093 Pneumonia. *Radiology* 299, E177-E186.
- 1094 Harker, J.A., and Lloyd, C.M. (2021). Overlapping and distinct features of viral and
1095 allergen immunity in the human lung. *Immunity* 54, 617-631.
- 1096 Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N.,
1097 Brightling, C., Ustianowski, A., Elmahi, E., *et al.* (2021). Dexamethasone in
1098 Hospitalized Patients with Covid-19. *N Engl J Med* 384, 693-704.
- 1099 Invernizzi, R., Wu, B.G., Barnett, J., Ghai, P., Kingston, S., Hewitt, R.J., Feary, J., Li,
1100 Y., Chua, F., Wu, Z., *et al.* (2021). The Respiratory Microbiome in Chronic
1101 Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis.
1102 *Am J Respir Crit Care Med* 203, 339-347.
- 1103 Jozwik, A., Habibi, M.S., Paras, A., Zhu, J., Guvenel, A., Dhariwal, J., Almond, M.,
1104 Wong, E.H.C., Sykes, A., Maybeno, M., *et al.* (2015). RSV-specific airway resident
1105 memory CD8+ T cells and differential disease severity after experimental human
1106 infection. *Nat Commun* 6, 10224.
- 1107 Kim, T.S., Hufford, M.M., Sun, J., Fu, Y.X., and Braciale, T.J. (2010). Antigen
1108 persistence and the control of local T cell memory by migrant respiratory dendritic
1109 cells after acute virus infection. *J Exp Med* 207, 1161-1172.
- 1110 Kory, P., and Kanne, J.P. (2020). SARS-CoV-2 organising pneumonia: 'Has there
1111 been a widespread failure to identify and treat this prevalent condition in COVID-19?'.
1112 *BMJ Open Respir Res* 7.
- 1113 Laing, A.G., Lorenc, A., Del Molino Del Barrio, I., Das, A., Fish, M., Monin, L., Munoz-
1114 Ruiz, M., McKenzie, D.R., Hayday, T.S., Francos-Quijorna, I., *et al.* (2020). A
1115 dynamic COVID-19 immune signature includes associations with poor prognosis. *Nat*
1116 *Med* 26, 1623-1635.
- 1117 Langfelder, P., and Horvath, S. (2008). WGCNA: an R package for weighted
1118 correlation network analysis. *BMC Bioinformatics* 9, 559.
- 1119 Lee, J., Park, H.K., Kwon, M.J., Ham, S.Y., Kim, J.M., Lim, S.Y., and Song, J.U.
1120 (2020). Decreased lung function is associated with elevated ferritin but not iron or
1121 transferrin saturation in 42,927 healthy Korean men: A cross-sectional study. *PLoS*
1122 *One* 15, e0231057.
- 1123 Li, Y., Zhang, Z., Yang, L., Lian, X., Xie, Y., Li, S., Xin, S., Cao, P., and Lu, J. (2020).
1124 The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2
1125 Spike. *iScience* 23, 101400.
- 1126 Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X.,
1127 Wang, F., *et al.* (2020). Single-cell landscape of bronchoalveolar immune cells in
1128 patients with COVID-19. *Nat Med* 26, 842-844.
- 1129 Lucas, C., Wong, P., Klein, J., Castro, T.B.R., Silva, J., Sundaram, M., Ellingson,
1130 M.K., Mao, T., Oh, J.E., Israelow, B., *et al.* (2020). Longitudinal analyses reveal
1131 immunological misfiring in severe COVID-19. *Nature* 584, 463-469.
- 1132 Mandal, S., Barnett, J., Brill, S.E., Brown, J.S., Denneny, E.K., Hare, S.S.,
1133 Heightman, M., Hillman, T.E., Jacob, J., Jarvis, H.C., *et al.* (2021). 'Long-COVID': a

Immune-proteome landscape post-COVID19

- 1134 cross-sectional study of persisting symptoms, biomarker and imaging abnormalities
1135 following hospitalisation for COVID-19. *Thorax* 76, 396-398.
- 1136 Mann, E.R., Menon, M., Knight, S.B., Konkel, J.E., Jagger, C., Shaw, T.N., Krishnan,
1137 S., Rattray, M., Ustianowski, A., Bakerly, N.D., *et al.* (2020). Longitudinal immune
1138 profiling reveals key myeloid signatures associated with COVID-19. *Sci Immunol* 5.
- 1139 Morimoto, Y., Hirahara, K., Kiuchi, M., Wada, T., Ichikawa, T., Kanno, T., Okano, M.,
1140 Kokubo, K., Onodera, A., Sakurai, D., *et al.* (2018). Amphiregulin-Producing
1141 Pathogenic Memory T Helper 2 Cells Instruct Eosinophils to Secrete Osteopontin and
1142 Facilitate Airway Fibrosis. *Immunity* 49, 134-150 e136.
- 1143 Myall, K.J., Mukherjee, B., Castanheira, A.M., Lam, J.L., Benedetti, G., Mak, S.M.,
1144 Preston, R., Thillai, M., Dewar, A., Molyneaux, P.L., and West, A.G. (2021).
1145 Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of
1146 Corticosteroid Treatment. *Ann Am Thorac Soc* 18, 799-806.
- 1147 Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M.V., McGroder, C., Stevens, J.S.,
1148 Cook, J.R., Nordvig, A.S., Shalev, D., Sehrawat, T.S., *et al.* (2021). Post-acute
1149 COVID-19 syndrome. *Nat Med* 27, 601-615.
- 1150 Raj, V.S., Mou, H., Smits, S.L., Dekkers, D.H., Muller, M.A., Dijkman, R., Muth, D.,
1151 Demmers, J.A., Zaki, A., Fouchier, R.A., *et al.* (2013). Dipeptidyl peptidase 4 is a
1152 functional receptor for the emerging human coronavirus-EMC. *Nature* 495, 251-254.
- 1153 Rodriguez, L., Pekkarinen, P.T., LakshmiKanth, T., Tan, Z., Consiglio, C.R., Pou, C.,
1154 Chen, Y., Mugabo, C.H., Nguyen, N.A., Nowlan, K., *et al.* (2020). Systems-Level
1155 Immunomonitoring from Acute to Recovery Phase of Severe COVID-19. *Cell Rep*
1156 *Med* 1, 100078.
- 1157 Ruan, Q., Yang, K., Wang, W., Jiang, L., and Song, J. (2020). Clinical predictors of
1158 mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan,
1159 China. *Intensive Care Med* 46, 846-848.
- 1160 Saris, A., Reijnders, T.D.Y., Nossent, E.J., Schuurman, A.R., Verhoeff, J., Asten,
1161 S.V., Bontkes, H., Blok, S., Duitman, J., Bogaard, H.J., *et al.* (2021). Distinct cellular
1162 immune profiles in the airways and blood of critically ill patients with COVID-19.
1163 *Thorax*.
- 1164 Schmidt, M.E., and Varga, S.M. (2018). The CD8 T Cell Response to Respiratory
1165 Virus Infections. *Front Immunol* 9, 678.
- 1166 Scott, N.A., Knight, S.B., Pearmain, L., Brand, O., Morgan, D.J., Jagger, C., Khan,
1167 S., Hackney, P., Smith, L., Menon, M., *et al.* (2020). Recovery of monocyte
1168 exhaustion is associated with resolution of lung injury in COVID-19 convalescence.
1169 *medRxiv*, 2020.2010.20207449.
- 1170 Sigfrid, L., Drake, T.M., Pauley, E., Jesudason, E.C., Olliaro, P., Lim, W.S., Gillesen,
1171 A., Berry, C., Lowe, D.J., McPeake, J., *et al.* (2021). Long Covid in adults discharged
1172 from UK hospitals after Covid-19: A prospective, multicentre cohort study using the
1173 ISARIC WHO Clinical Characterisation Protocol. *medRxiv*,
1174 2021.2003.2018.21253888.
- 1175 Slutter, B., Pewe, L.L., Kaech, S.M., and Harty, J.T. (2013). Lung airway-surveilling
1176 CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A
1177 virus. *Immunity* 39, 939-948.
- 1178 Slutter, B., Van Braeckel-Budimir, N., Abboud, G., Varga, S.M., Salek-Ardakani, S.,
1179 and Harty, J.T. (2017). Dynamics of influenza-induced lung-resident memory T cells
1180 underlie waning heterosubtypic immunity. *Sci Immunol* 2.
- 1181 Striz, I., Wang, Y.M., Svarcova, I., Trnka, L., Sorg, C., and Costabel, U. (1993). The
1182 phenotype of alveolar macrophages and its correlation with immune cells in
1183 bronchoalveolar lavage. *Eur Respir J* 6, 1287-1294.
- 1184 Szabo, P.A., Dogra, P., Gray, J.I., Wells, S.B., Connors, T.J., Weisberg, S.P.,
1185 Krupska, I., Matsumoto, R., Poon, M.M.L., Idzikowski, E., *et al.* (2021). Longitudinal
1186 profiling of respiratory and systemic immune responses reveals myeloid cell-driven
1187 lung inflammation in severe COVID-19. *Immunity* 54, 797-814 e796.

Immune-proteome landscape post-COVID19

- 1188 Szabo, P.A., Miron, M., and Farber, D.L. (2019). Location, location, location: Tissue
1189 resident memory T cells in mice and humans. *Sci Immunol* 4.
1190 Thwaites, R.S., Sanchez Sevilla Uruchurtu, A., Siggins, M.K., Liew, F., Russell, C.D.,
1191 Moore, S.C., Fairfield, C., Carter, E., Abrams, S., Short, C.E., *et al.* (2021).
1192 Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-
1193 CSF in severe COVID-19. *Sci Immunol* 6.
1194 Wang, E.Y., Mao, T., Klein, J., Dai, Y., Huck, J.D., Liu, F., Zheng, N.S., Zhou, T.,
1195 Israelow, B., Wong, P., *et al.* (2020). Diverse Functional Autoantibodies in Patients
1196 with COVID-19. medRxiv, 2020.2012.2010.20247205.
1197 Wichmann, D., Sperhake, J.P., Lutgehetmann, M., Steurer, S., Edler, C., Heinemann,
1198 A., Heinrich, F., Mushumba, H., Kniep, I., Schroder, A.S., *et al.* (2020). Autopsy
1199 Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective
1200 Cohort Study. *Ann Intern Med* 173, 268-277.
1201 Wu, T., Hu, Y., Lee, Y.T., Bouchard, K.R., Benechet, A., Khanna, K., and Cauley,
1202 L.S. (2014). Lung-resident memory CD8 T cells (TRM) are indispensable for optimal
1203 cross-protection against pulmonary virus infection. *J Leukoc Biol* 95, 215-224.
1204 Yamashita, C.M., Dolgonos, L., Zemans, R.L., Young, S.K., Robertson, J., Briones,
1205 N., Suzuki, T., Campbell, M.N., Gaudie, J., Radisky, D.C., *et al.* (2011). Matrix
1206 metalloproteinase 3 is a mediator of pulmonary fibrosis. *Am J Pathol* 179, 1733-1745.
1207 Zhang, B., and Horvath, S. (2005). A general framework for weighted gene co-
1208 expression network analysis. *Stat Appl Genet Mol Biol* 4, Article17.
1209




Figure 1: Altered immune cell profile in post-COVID19 BAL over 80 days post discharge

(A) Schematic of study design. BAL and blood were sampled from healthy donors and at > 80 days after hospital discharge from post-COVID19 patients. Traditional and spectral flow cytometry and Olink proteomics was performed on BAL and plasma and correlated with clinical parameters. **(B)** Left: Total number of cells in BAL from healthy controls and post-COVID19 patients. Right: total number of cells in BAL from post-COVID19 patients, stratified according to severity of the acute illness. **(C)** Total cell numbers of immune populations ($\times 10^6/\text{ml}$) in BAL from healthy controls and post-COVID19 patients, based on gating shown in Methods Figure 1.

Data are presented as mean \pm SEM. Healthy controls $n = 16$, post-COVID19 patients $n = 21$, moderate $n = 6$, severe $n = 8$, very severe $n = 7$. Statistical significance was tested by Mann Whitney U test or Kruskal Wallis test + Dunn's multiple comparison test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.005$, **** $P < 0.001$.




Figure 2: A distinct proteome is present in the post COVID-19 airway

436 proteins in BAL and plasma 435 proteins were measured using Olink immunoassays in post-COVID19 patients (n = 19) and healthy controls (n = 9). **(A)** Principal component analysis (PCA) of BAL and plasma proteomes: each point represents a sample. **(B)** Left: heatmap displaying Z-score normalised protein abundance for the 22 proteins that were significantly differentially abundant (5% FDR) between post-COVID19 and healthy controls in BAL. Samples have been ordered by case control status and then by peak severity during acute COVID-19 infection. Proteins are ordered by hierarchical clustering. Right: heatmap for these same 22 proteins in plasma, presented in the same order as for BAL. **(C)** Volcano plot showing differentially protein abundance analysis between post-COVID19 patients and healthy controls in BAL. Nominal $-\log_{10} P$ values are shown. Significantly differentially abundant proteins (5% FDR) are coloured in red and labelled. **(D)** BAL and plasma normalised protein abundance (NPX) expression for the 5 most significantly differentially abundant proteins between post-COVID19 patients and healthy controls. P_{BH} = Benjamini-Hochberg adjusted p-values. **(E)** Correlation between the 22 differentially abundant proteins and immune cell frequency in BAL.

A

Module	Correlation	p_val	p_fdr	p_bonferroni
red	0.53	0.00	0.03	0.03
blue	0.50	0.01	0.03	0.07
black	0.38	0.04	0.11	0.40
turquoise	0.38	0.05	0.11	0.43
brown	0.34	0.08	0.15	0.73
yellow	0.28	0.16	0.22	1.00
grey	-0.26	0.17	0.22	1.00
pink	0.03	0.86	0.91	1.00
green	-0.02	0.91	0.91	1.00





Figure 3: A network of proteins linked to immune cell chemotaxis and cell death is upregulated in the BAL post-COVID19

WGCNA of BAL proteome of post-COVID19 patients and healthy controls. **(A)** Associations of protein modules identified by WGCNA with case-control status (post-COVID19 or healthy). **(B)** Heatmap displaying Z-score normalised protein abundance for the 37 proteins that form the 'red' protein module. Samples are ordered according to clinical status. Severity refers to peak severity of the acute COVID19 episode. Proteins are ordered by hierarchical clustering. **(C)** Right: Network representation of proteins in the red module and their interconnections defined using String-db. An edge in the network represents a relationship between proteins, coloured according to the type of evidence for the connection (see Methods). Left: list of hub proteins within the network (with hub proteins that were also significantly differentially upregulated in post-COVID19 patient BAL highlighted in red).




Figure 4. CXCR3 ligands and markers of epithelial damage correlate with CD8 T cells in the airways

BAL immune cells and protein concentrations were analysed post-COVID19 infection. **(A)** Linear regression analysis was conducted between $n = 435$ proteins measured in the BAL using the Olink platform and BAL immune cell frequencies identified by flow cytometry as shown in Figure 1. A heatmap showing proteins with the highest correlation versus 5 major immune cell frequencies is shown. **(B-C)** For each sample, protein levels for CXCL9, -10 and -11, were normalised to the median level in healthy controls. For each sample, the mean of the normalised values for the 3 proteins was calculated to provide a summary metric for CXCR3 chemokines. This was then plotted against versus **(B)** T, NK and NKT proportions in post-COVID19 patients and healthy controls and **(C)** monocyte frequencies and subsets in post-COVID19 patients only. **(D)** BAL T cell frequency versus CD4 and CD8a concentrations as measured by Olink. **(E)** CD8a concentration versus CASP3, EPCAM, MB and DPP4 in the airways. **(F)** DPP4, albumin and LDH concentrations in the BAL determined by ELISA. Data are presented as median \pm IQR. **(A)** Pearsons correlation of $n = 19$ post-COVID19 patients, the r value is shown. **(B-E)** Each point represents an individual patient, linear regression line \pm 95% confidence intervals are depicted, and r and p values from Pearsons correlation are stated. **(F)** represents $n = 38$ post-COVID19 and $n = 20$ healthy control individuals. Statistics were conducted using Mann-Whitney U test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.005$, **** $P < 0.001$. pCOVID = post-COVID19.




Figure 5. Myeloid cell frequencies are not linked to indications of ongoing damage in the post-COVID19 airway

BAL and blood immune cells from post-COVID19 patients were analyzed by spectral deconvolution cytometry. **(A)** Heatmap of normalised median expression of myeloid cell modulatory and subset markers by clusters of myeloid cells in the airways identified by FlowSOM analysis. **(B)** Violin plot showing frequencies of each cluster in BAL and blood. **(C)** Violin plots showing classical, non-classical and intermediate monocyte subsets as proportions of live leukocytes in BAL and blood identified by manual gating. **(D)** Violin plots showing pDC, cDC1 and cDC2 cell proportions in BAL and blood. **(E)** Geometric mean fluorescence intensity of activation markers expressed by CD11c⁺ monocytes. **(F)** Pearson's correlation between BAL myeloid subsets (as a % of leukocytes) and airway LDH, albumin and DPP4. Data are presented as median \pm IQR. Each point represents an individual patient. Statistical significance for **(B)**, **(C)** and **(D)** was tested by Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.




Figure 6. The airways of post-COVID19 patients are enriched for activated CD8 TRM cells
 BAL and blood immune cells from post-COVID19 patients were analyzed by spectral deconvolution cytometry. **(A)** Heatmap of normalised median expression of T cell modulatory and subset markers by clusters of T cells in the airways identified by FlowSOM analysis. **(B)** Violin plot showing frequencies of each cluster in BAL and blood. **(C)** tSNE projection of clusters identified by FlowSOM analysis in BAL and blood. **(D)** Violin plots showing CD4+ and CD8+ T cell subsets as proportions of all T cells in BAL and blood identified by manual gating. **(E)** Violin plots showing gd, NK, NKT and MAIT cell proportions in BAL and blood. **(F)** Pearson correlations between total airway CD4+ and CD8+ T cell numbers and subsets. **(G)** Heatmap depicting Pearson correlation between different T cell populations (as a % of BAL leukocytes) and the concentration of DPP4, LDH and Albumin in the airways. **(H)** Pearson correlations between the gMFI of LDH and albumin. Data are presented as median \pm IQR. Each point represents an individual patient. **(A, B, E and F)** represent $n = 20$ individuals. **(C)** represents an equal number of cells from $n = 10$ patients combined. **(G & H)** represents $n = 18$ individuals. Statistical significance for **(B), (D), (E) and (G)** was tested by Mann-Whitney U test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.005$, **** $P < 0.001$.




Figure 7. Reduced cellularity in the airways one year after initial bronchoscopy post-COVID19
(A) Total cell counts (left) and proportions of lymphocytes (right) in the BAL following first bronchoscopy and one year follow-up bronchoscopy. **(B)** Cell counts of lymphocyte populations in the BAL following first bronchoscopy and one year follow-up bronchoscopy. **(C)** Cell counts of myeloid populations in the BAL following first bronchoscopy and one year follow-up bronchoscopy. **(D)** Proportions of T cell subsets in the BAL following first bronchoscopy and one year follow-up bronchoscopy. **(E)** LDH (left) and albumin (right) measurements in BAL following first year bronchoscopy and one year follow-up bronchoscopy. **(F)** Percentage of abnormal CT following first year CT and one year follow-up CT. **(G)** BAL LDH and albumin quantification following first year bronchoscopy and one year follow-up bronchoscopy. Each point represents a single patient. Green shading indicates median \pm IQR for proportions of populations and mediator levels observed in healthy airways.